- Home
- SES vs CTMX Comparison
SES vs CTMX Comparison
Compare SES & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SES
- CTMX
- Stock Information
- Founded
- SES 2012
- CTMX 2008
- Country
- SES United States
- CTMX United States
- Employees
- SES N/A
- CTMX N/A
- Industry
- SES Auto Parts:O.E.M.
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- SES Consumer Discretionary
- CTMX Health Care
- Exchange
- SES Nasdaq
- CTMX Nasdaq
- Market Cap
- SES 340.3M
- CTMX 380.9M
- IPO Year
- SES N/A
- CTMX 2015
- Fundamental
- Price
- SES $1.09
- CTMX $1.91
- Analyst Decision
- SES Hold
- CTMX Strong Buy
- Analyst Count
- SES 3
- CTMX 3
- Target Price
- SES $1.50
- CTMX $5.67
- AVG Volume (30 Days)
- SES 8.6M
- CTMX 3.1M
- Earning Date
- SES 08-04-2025
- CTMX 08-07-2025
- Dividend Yield
- SES N/A
- CTMX N/A
- EPS Growth
- SES N/A
- CTMX 263.20
- EPS
- SES N/A
- CTMX 0.49
- Revenue
- SES $11,360,000.00
- CTMX $141,100,000.00
- Revenue This Year
- SES $916.42
- CTMX N/A
- Revenue Next Year
- SES $151.67
- CTMX N/A
- P/E Ratio
- SES N/A
- CTMX $3.91
- Revenue Growth
- SES N/A
- CTMX 18.01
- 52 Week Low
- SES $0.20
- CTMX $0.40
- 52 Week High
- SES $2.53
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- SES 49.36
- CTMX 39.81
- Support Level
- SES $0.99
- CTMX $1.72
- Resistance Level
- SES $1.21
- CTMX $2.43
- Average True Range (ATR)
- SES 0.10
- CTMX 0.20
- MACD
- SES -0.03
- CTMX -0.06
- Stochastic Oscillator
- SES 25.32
- CTMX 26.84
About SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.